Initial antiretroviral regimens: In general three drugs are better than two are better than one

BMJ

Volumn 324, Issue 7340, 2002, Pages 747-748

  Carpenter, Charles ^a  

^a MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

DRUG EFFICACY; DRUG MIXTURE; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HIV INFECTIONS; HUMANS;

EID: 0037196943     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.324.7340.747     Document Type: Editorial

References (9)

1. Jordan R, Gold L, Cummins C, Hyde C. For increasing numbers of drugs in antiretroviral combination therapy. Systematic review and meta-analysis of evidence. BMJ 2002; 324: 757–760.
2. Pozniak A, Gazzard BG, Churchill D, Johnson MA, Williams I, Deutsch JC, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. BHIVA writing committee on behalf of the BHIVA executive committee. HIV Medicine 2001; 2: 276–313.
3. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society—USA Panel. JAMA 2000; 283: 381–390.
4. Fauci AS, Bartlett JG, Goosby E, Kates J. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. www.hivatis.org/trtgdlns.html, 13 Aug 2001 (accessed 12 December 2001).
5. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunological response in HIV-1 infected subjects receiving potent antiretroviral therapy. AIDS 2000; 14: 959–969.
6. Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63: 865–870.
7. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, et al. aBT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrobol Agents Chemo Ther 1998; 42: 3218–3224.
8. Pantaleo G, Cohen OJ, Schacker T, Vaccarezza M, Graziosi C, Rizzardi GP, et al. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy. Nat Med 1998; 4: 341–344.
9. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999; 179: 1375–1381.